On-Label Versus Off-Label Use of Recombinant Activated Factor VII: A Comprehensive Review of Use in Two Canadian Centers

Seminars in Hematology

Volumn 45, Issue SUPPL. 1, 2008, Pages

  Carcao, Manuel D ^a,b   Webert, Kathryn E ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Division of Hematology   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING INHIBITOR; DESMOPRESSIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; VITAMIN K GROUP;

ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CANADA; DRUG USE; GLANZMANN DISEASE; HEMOPHILIA; HUMAN; PRIORITY JOURNAL; THROMBOCYTE DYSFUNCTION; TREATMENT INDICATION;

BLOOD PLATELET DISORDERS; CANADA; FACTOR VII DEFICIENCY; FACTOR VIIA; HUMANS; MEDICAL AUDIT; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 44849135485     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.03.003     Document Type: Article

References (11)

1. Boffard K.D., Riou B., Warren B., Choong P.I., Rizoli S., Rossaint R., et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59 (2005) 8-15
2. Mayer S.A., Brun N.C., Begtrup K., Broderick J., Davis S., Diringer M.N., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352 (2005) 777-785
3. Johansson P.I., Eriksen K., Nielsen S.L., Rojkjaer R., and Alsbjørn B. Recombinant FVIIa decreases perioperative blood transfusion requirement in burn patients undergoing excision and skin grafting-Results of a single centre pilot study. Burns 33 (2007) 435-440
4. Warren O., Mandal K., Hadjianastassiou V., Knowlton L., Panesar S., John K., et al. Recombinant activated factor VII in cardiac surgery: A systematic review. Ann Thorac Surg 83 (2007) 707-714
5. Friederich P.W., Henny C.P., Messelink E.J., Geerdink M.G., Keller T., Kurth K.H., et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: A double-blind placebo-controlled randomised trial. Lancet 36 (2003) 201-205
6. Agarwal N., Spahr J.E., and Rodgers G.M. Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): A case report and review of the literature on approved and off-label use of rFVIIa. Blood Coagul Fibrinolysis 18 (2007) 205-207
7. Coppola A., Simone C.D., Palmieri N.M., Coppola D., Lanza F., Ruosi C., et al. Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome. Blood Coagul Fibrinolysis 18 (2007) 199-201
8. Wrǒbel G., Dobaczewski G., Patkowski D., Sokół A., and Grotthus E. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Pediatr Blood Cancer 47 suppl (2006) 729-730
9. Ingerslev J., Vanek T., and Culic S. Use of recombinant factor VIIa for emergency reversal of anticoagulation. J Postgrad Med 53 (2007) 17-22
10. Heller M., Lau W., Pazmino-Canizares J., Brandão L.R., and Carcao M. A comprehensive review of rFVIIa use in a tertiary care pediatric center. Pediatr Blood Cancer 50 (2008) 1013-1017
11. Webert K.E., Arnold D.M., Carruthers J., Molnar L., Almonte T., Decker K., et al. Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia. Haemophilia 13 (2007) 518-526